CYP102A1 (BM3) is a catalytically self‐sufficient flavocytochrome fusion protein isolated from Bacillus megaterium, which displays similar metabolic capabilities to many drug‐metabolizing human P450 isoforms. BM3′s high catalytic efficiency, ease of production and malleable active site makes the enzyme a desirable tool in the production of small molecule metabolites, especially for compounds that exhibit drug‐like chemical properties. The engineering of select key residues within the BM3 active site vastly expands the catalytic repertoire, generating variants which can perform a range of modifications. This provides an attractive alternative route to the production of valuable compounds that are often laborious to synthesize via traditional organic means. Extensive studies have been conducted with the aim of engineering BM3 to expand metabolite production towards a comprehensive range of drug‐like compounds, with many key examples found both in the literature and in the wider industrial bioproduction setting of desirable oxy‐metabolite production by both wild‐type BM3 and related variants. This review covers the past and current research on the engineering of BM3 to produce drug metabolites and highlights its crucial role in the future of biosyn-thetic pharmaceutical production.
|Number of pages||23|
|Journal||International Journal of Molecular Sciences|
|Early online date||21 Oct 2021|
|Publication status||Published - 1 Nov 2021|